Picard Medical (NYSE American: PMI) has announced that a 29-year-old patient successfully received a donor heart transplant after more than four years of being fully supported by the SynCardia Total Artificial Heart—SynCardia System’s parent company is Picard.
The SynCardia Total Artificial Heart is the world’s first of its kind approved by the FDA and Health Canada.
In a statement, Patrick NJ Schnegelsberg, CEO of Picard, commented, “The challenge in advanced heart failure is often the time required to find a suitable donor organ. This case demonstrates how the SynCardia Total Artificial Heart can sustain critically ill patients for extended periods, allowing them to live at home while awaiting heart transplantation.”
